$3.59
0.28%
Nasdaq, Aug 22, 10:02 pm CET
ISIN
CA03879J1003
Symbol
ABUS

Arbutus Biopharma Corporation Stock price

$3.59
+0.44 13.97% 1M
+0.25 7.49% 6M
+0.32 9.79% YTD
-0.22 5.77% 1Y
+1.30 56.77% 3Y
+0.58 19.27% 5Y
-3.34 48.20% 10Y
-3.63 50.26% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.01 0.28%
ISIN
CA03879J1003
Symbol
ABUS
Industry

Key metrics

Basic
Market capitalization
$688.2m
Enterprise Value
$590.1m
Net debt
positive
Cash
$98.1m
Shares outstanding
191.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
44.6 | 107.9
EV/Sales
38.3 | 92.5
EV/FCF
negative
P/B
8.3
Financial Health
Equity Ratio
73.9%
Return on Equity
-71.8%
ROCE
-44.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$15.4m | $6.4m
EBITDA
$-42.3m | -
EBIT
$-43.3m | $-55.6m
Net Income
$-54.3m | $-52.3m
Free Cash Flow
$-60.3m
Growth (TTM | estimate)
Revenue
53.3% | 3.4%
EBITDA
48.3% | -
EBIT
48.0% | 23.5%
Net Income
29.6% | 25.2%
Free Cash Flow
17.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-274.5% | -
EBIT
-281.1%
Net
-351.9% | -819.8%
Free Cash Flow
-391.0%
More
EPS
$-0.3
FCF per Share
$-0.3
Short interest
9.6%
Employees
44
Rev per Employee
$140.0k
Show more

Is Arbutus Biopharma Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Arbutus Biopharma Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Arbutus Biopharma Corporation forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Arbutus Biopharma Corporation forecast:

Buy
80%
Hold
20%

Financial data from Arbutus Biopharma Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
15 15
53% 53%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
23% 23%
119%
- Research and Development Expense 38 38
45% 45%
243%
-42 -42
48% 48%
-274%
- Depreciation and Amortization 1.01 1.01
30% 30%
7%
EBIT (Operating Income) EBIT -43 -43
48% 48%
-281%
Net Profit -54 -54
30% 30%
-352%

In millions USD.

Don't miss a Thing! We will send you all news about Arbutus Biopharma Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arbutus Biopharma Corporation Stock News

Positive
The Motley Fool
18 days ago
Arbutus (ABUS) Q2 Revenue Surges 529%
Neutral
GlobeNewsWire
19 days ago
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran
Neutral
GlobeNewsWire
2 months ago
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China
More Arbutus Biopharma Corporation News

Company Profile

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Head office Canada
CEO Lindsay Androski
Employees 44
Founded 2005
Website www.arbutusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today